介绍小化合物,如L-亮氨酸可以通过阻断某些作用来促进骨骼再生,通过信号序列引发细胞反应。这项研究探索了在开发的新型移植材料上结合L-亮氨酸和透明质酸如何影响骨进行骨构建过程的能力。材料和方法本研究设计为体外实验,其中通过将L-亮氨酸与透明质酸整合并掺入基于羟基磷灰石的绵羊骨移植材料中来配制新型骨移植物。修改烧结程序以包括氨基酸L-精氨酸。使用扫描电子显微镜等方法进行全面检查,X射线衍射术,傅里叶变换红外光谱(FTIR),MTT(3-(4,5-二甲基噻唑-2-基)-2,5-二苯基四唑溴化物)测定,和骨形成测定。这些分析与商业上可获得的未改变的Bio-Oss的特征并列,专注于它们的物理化学性质。将性能与市售的骨移植材料进行比较。结果烧结的羟基磷灰石/L-亮氨酸接枝显示出互连的孔结构,表明较高的烧结和固结影响羟基磷灰石,通过扫描电子显微镜观察。X射线衍射(XRD)分析证实了烧结绵羊骨样品中的羟基磷灰石,确认其适用于各种生物医学应用。在骨形成试验中,光密度(OD)值为61%的羟基磷灰石/L-精氨酸接枝,Bio-Oss组的58%,对照组为51%。MTT法,评估细胞活力和代谢活性,在24小时时证明了所有样品的生物相容性和细胞生长。结论通过将L-亮氨酸与透明质酸结合到新型植骨材料中用于植骨,证明与现有骨组织的相容性增强。然而,这种组合方法的具体优势尚不完全清楚。必须进行更多的研究来揭示这种协同作用是如何工作的,评估其长期影响,进行临床试验,并增强这种混合物在植骨手术中的实际应用的有效性。
Introduction Small compounds like L-leucine can boost bone regrowth by blocking certain effects, sparking cell reactions through signaling sequences. This research explored how combining L-leucine with hyaluronic acid on the developed novel graft material affects the bone\'s ability to conduct bone-building processes. Material and methods This study was designed as an in-vitro experiment, where a novel bone graft was formulated by integrating L-leucine with hyaluronic acid and incorporated into a hydroxyapatite-based ovine bone graft material. The sintering procedure was modified to include the amino acid L-arginine. Comprehensive examinations were executed using methodologies such as scanning electron microscopy, X-ray diffractometry, Fourier-transform infrared spectroscopy (FTIR), MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay, and bone formation assay. These analyses were juxtaposed with the characteristics of the commercially accessible unaltered Bio-Oss, focusing on their physicochemical properties. The properties were compared with a commercially available bone graft material. Results The sintered hydroxyapatite/L-leucine graft displayed an interconnected pore structure, indicating that higher sintering and consolidation affected hydroxyapatite, as observed through scanning electron microscopy. X-ray diffraction (XRD) analysis confirmed hydroxyapatite in the sintered ovine bone samples, affirming their suitability for various biomedical applications. In the bone formation assay, optical density (OD) values were 61% for the hydroxyapatite/L-arginine graft, 58% for the Bio-Oss group, and 51% for the control group. The MTT assay, which assesses cell viability and metabolic activity, demonstrated biocompatibility and cell growth for all samples at 24 hours. Conclusion The research noted beneficial outcomes by incorporating L-leucine into the novel bone graft material with hyaluronic acid for bone grafting, demonstrating enhanced compatibility with existing bone tissue. However, the specific advantages of this combined approach are not fully known. It is essential to conduct more studies to uncover how this synergy works, assess its prolonged impacts, carry out clinical tests, and enhance the effectiveness of this blend for practical applications in bone graft surgeries.